Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Sep 15, 2024; 16(9): 3905-3912
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3905
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3905
Table 5 Univariate and multivariate analyses for progression-free survival and overall survival
Factor | Univariate analysis, HR (95%CI) | P value | Multivariate analysis, HR (95%CI) | P value |
PFS | ||||
CEA (≥ 50% vs < 50% reduction) | 0.45 (0.23-0.88) | 0.020 | 0.40 (0.20-0.82) | 0.012 |
CA19-9 (≥ 50% vs < 50% reduction) | 0.50 (0.26-0.97) | 0.040 | 0.58 (0.29-1.16) | 0.123 |
CA72-4 (≥ 50% vs < 50% reduction) | 0.48 (0.24-0.94) | 0.032 | 0.55 (0.27-1.12) | 0.098 |
CD4+ /CD8+ ratio (≥ 1.5 vs < 1.5) | 0.42 (0.21-0.84) | 0.014 | 0.45 (0.22-0.92) | 0.028 |
OS | ||||
CEA (≥ 50% vs < 50% reduction) | 0.52 (0.25-1.08) | 0.080 | 0.60 (0.28-1.30) | 0.197 |
CA19-9 (≥ 50% vs < 50% reduction) | 0.55 (0.27-1.13) | 0.103 | 0.70 (0.33-1.50) | 0.361 |
CA72-4 (≥ 50% vs < 50% reduction) | 0.43 (0.20-0.92) | 0.030 | 0.38 (0.17-0.85) | 0.018 |
CD4+ /CD8+ ratio (≥ 1.5 vs < 1.5) | 0.40 (0.18-0.87) | 0.021 | 0.42 (0.19-0.93) | 0.033 |
- Citation: Zheng CW, Yang YM, Yang H. Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer. World J Gastrointest Oncol 2024; 16(9): 3905-3912
- URL: https://www.wjgnet.com/1948-5204/full/v16/i9/3905.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i9.3905